HS 293719 Other
Quick Answer: HS code 2937.19, "Other," covers a diverse range of protein hormones and their derivatives not elsewhere specified within subheading 2937.1. This includes various synthetic or natural protein-based hormones used in pharmaceuticals and biological research, excluding pituitary (somatotropin), insulin, and ACTH. For importers and exporters, understanding the specific product is crucial due to varying duty rates. The UK and EU generally apply a 0.00% ad valorem duty rate. In contrast, the US imposes a "Free" rate for most favored nation (MFN) treatment, but certain origins or specific product types may be subject to a 25% ad valorem duty under Section 301 tariffs, as outlined by the USITC. Importers should verify the exact product classification and country of origin to determine the applicable US duty rate.
What Are the Import Duty Rates?
🇬🇧 United Kingdom
| Code | MFN | Preferential | Unit |
|---|---|---|---|
| 2937190000 | 0.00 % | — | — |
🇪🇺 European Union (TARIC)
| Code | MFN | Preferential | Unit |
|---|---|---|---|
| 2937190000 | 0.00 % | — | — |
🇺🇸 United States (HTSUS)
| Code | MFN | Preferential | Unit |
|---|---|---|---|
| 2937190000 | Free | — | ["g"] |
Duty rates sourced from the USITC (US International Trade Commission) Harmonized Tariff Schedule (HTS) (accessed 2/22/2026), EU TARIC – DG TAXUD (Directorate-General for Taxation and Customs Union) (accessed 2/22/2026), and UK Trade Tariff – HMRC (His Majesty's Revenue and Customs) (accessed 2/22/2026).
Data compiled and presented by HSRates.
How Has Trade Volume Developed?
Trade Volume 2023
How to Classify This HS Code?
What products does HS 293719 cover?
This subheading covers other hormones, prostaglandins, thromboxanes, and leukotrienes, natural or reproduced by synthesis, and their derivatives and structural analogues, including chain modified polypeptides, used primarily for their hormonal action, not elsewhere specified or included within HS 2937. This specifically encompasses a broad range of complex organic chemical compounds that exert physiological effects at very low concentrations, provided they are not specifically listed in other subheadings under Heading 2937, such as pituitary or adrenal cortical hormones. The WCO Harmonized System Explanatory Notes for Chapter 29 provide guidance on the chemical structure and primary function required for classification here, further elaborated by the USITC Harmonized Tariff Schedule and EU TARIC definitions.
What falls outside HS 293719?
The following products are excluded from HS 293719: pituitary (anterior) or similar hormones (e.g., somatotropin, chorionic gonadotropin) which are classified under HS 293711; adrenal cortical hormones (e.g., cortisone, hydrocortisone, prednisone) found under HS 293721; and other steroid hormones (e.g., estrogens, progestins, androgens) classified under HS 293729. Additionally, antibiotics with hormonal activity are generally classified in Chapter 29, but under their specific antibiotic subheadings, not as hormones. Vitamins, even if they have some regulatory functions, are classified under HS 2936. Preparations of hormones for therapeutic or prophylactic uses, put up in measured doses or in forms or packings for retail sale, are excluded and classified in Chapter 30, specifically under HS 3003 or HS 3004.
What are common classification mistakes for HS 293719?
A common error is misclassifying specific hormones that have their own dedicated subheadings within Heading 2937, such as pituitary or adrenal cortical hormones, into the "other" category of HS 293719. Importers sometimes overlook the specific enumeration of certain hormones, leading to incorrect application of General Interpretative Rule (GRI) 1, which prioritizes specific descriptions over general ones. Another frequent mistake involves classifying hormone preparations in bulk as raw materials under HS 293719, when they are actually put up in measured doses or for retail sale, which would correctly place them in Chapter 30 under GRI 3(a) or 6. Furthermore, products that are structural analogues but lack the primary hormonal action are often incorrectly included, when their primary function might dictate classification elsewhere in Chapter 29 or even another chapter entirely.
How should importers classify products under HS 293719?
The correct procedure for classifying products under HS 293719 involves a meticulous review of the product's chemical structure, its primary physiological function, and its presentation. Importers and customs brokers must first confirm that the substance is indeed a hormone, prostaglandin, thromboxane, or leukotriene, or a derivative/analogue thereof, as defined by the WCO HS Explanatory Notes for Chapter 29. Subsequently, they must exhaustively check all other specific subheadings within Heading 2937 (e.g., 293711, 293721, 293729) to ensure the product is not more specifically described elsewhere. If the product is not specifically enumerated and meets the general criteria for hormones, then HS 293719 is appropriate. Finally, it is crucial to verify that the product is not put up in measured doses or for retail sale, as this would necessitate classification in Chapter 30, requiring careful application of GRI 3(a) and 6.
Which HS Codes Are Related?
Not the right code? Search all HS codes to find the correct tariff classification.
FAQ
What is the import duty rate for products classified under HS 2937.19 in the United States, European Union, and United Kingdom?
For products classified under HS 2937.19 ('Other' pituitary and other hormones and their derivatives), the Most Favored Nation (MFN) duty rates are generally as follows: In the United States, the MFN (Normal Trade Relations) duty rate is 0.00% ad valorem, as per the Harmonized Tariff Schedule of the United States (HTSUS) 2937.19.00.00. In the European Union, the MFN duty rate (Third Country Duty) is also 0.00% ad valorem, as indicated in the TARIC database for CN code 2937 19 00. Similarly, the UK Global Tariff (UKGT) for commodity code 2937 19 00 00 applies a duty rate of 0.00% ad valorem. Importers should always verify the latest rates via the official USITC HTSUS, EU TARIC, or UK Trade Tariff portals, as rates can be subject to change or specific conditions.
What are the key classification criteria for HS 2937.19, and what types of products fall under 'Other'?
HS 2937.19 is a residual subheading under 2937.1 ('Pituitary and other hormones and their derivatives'). Products are classified here if they are hormones or their derivatives, not specifically provided for in subheadings 2937.11 (Somatotropin, its derivatives and structural analogues) or 2937.12 (Insulin and its salts). This 'Other' category typically includes a wide range of pituitary hormones (excluding somatotropin), adrenal cortical hormones, thyroid hormones, parathyroid hormones, and their synthetic or natural derivatives, provided they are chemically defined and not mixtures or preparations of Chapter 30. Classification requires a precise chemical identification of the hormone or derivative. Reference to the Explanatory Notes to the Harmonized System for Chapter 29 and heading 29.37 is crucial for accurate determination.
Are there any preferential duty rates available for HS 2937.19 under common trade agreements, and how can importers claim them?
Yes, preferential duty rates, often 'Free' or 0.00%, are frequently available for HS 2937.19 under various Free Trade Agreements (FTAs) and preferential trade programs. For instance, products originating from countries with an FTA with the importing country (e.g., USMCA for the US, EU-Japan EPA for the EU, or UK-Australia FTA for the UK) may qualify for duty-free treatment. To claim preferential rates, importers must ensure the goods meet the specific Rules of Origin (ROO) of the relevant agreement. This typically involves providing a valid Certificate of Origin or an origin declaration from the exporter, demonstrating that the product was wholly obtained or underwent sufficient processing in the beneficiary country. Importers should consult the specific FTA text and the importing country's customs regulations (e.g., CBP regulations for the US) for detailed origin requirements and documentation.
What specific documentation is required for the importation of products under HS 2937.19, beyond standard customs documents?
Beyond standard commercial invoices, packing lists, and bills of lading/air waybills, the importation of products under HS 2937.19 often necessitates additional regulatory documentation due to their nature as hormones or pharmaceutical intermediates. In many countries, these products are subject to health and safety regulations. Importers may need to provide:
- Certificates of Analysis (CoA): Detailing the chemical composition, purity, and specifications of the hormone or derivative.
- Material Safety Data Sheets (MSDS/SDS): For hazardous substances.
- Import Permits/Licenses: Issued by national health authorities (e.g., FDA in the US, EMA for the EU, MHRA for the UK) if the product is intended for pharmaceutical use, clinical trials, or is a controlled substance.
- End-Use Certificates: In some cases, to confirm the product's intended application (e.g., research vs. human consumption). It is critical for importers to verify specific requirements with the relevant regulatory bodies in the importing country prior to shipment to avoid delays or penalties.
Could HS 2937.19 products be subject to anti-dumping or countervailing duties (AD/CVD)?
While less common for highly specialized pharmaceutical intermediates like hormones, products classified under HS 2937.19 could potentially be subject to Anti-Dumping (AD) or Countervailing Duties (CVD) if investigations determine that they are being dumped (sold below fair value) or unfairly subsidized by the exporting country, causing material injury to a domestic industry. Importers should regularly check official trade remedy databases of the importing country (e.g., US Department of Commerce and ITC for the US, EU Commission's Trade Defence website, UK Trade Remedies Authority) for any ongoing investigations or existing AD/CVD orders specific to this HS code or broader product categories that might encompass these hormones. Failure to account for applicable AD/CVD can result in significant additional duties and penalties.